Sodium Hyaluronate

ExcipientCAS 9067-32-7UNII YSE9PPT4TH

2 organisations hold 2 active FDA Type IV Drug Master Files for Sodium Hyaluronate. 2 further filings are inactive and shown as history. 49 valid EDQM Certificates of Suitability are on record for the same substance.

Sources: FDA List of Drug Master Files (checked 13 Nov 2026); FDA Global Substance Registration System (identity); EDQM Certification Online Database. Methodology

Active Type IV DMFs (2)

HolderDMFFiled asSubmitted
MUBY CHEM PRIVATE LTD
India
41115SODIUM HYALURONATE BPApr 2025
ANMOL CHEMICALS PRIVATE LTD40916SODIUM HYALURONATE BPDec 2024

“Filed as” is the subject exactly as the holder gave it to the FDA, including the grade or pharmacopoeia it names. Holder names link to a company profile where one is published. An active filing can be referenced by a drug application; it is not proof of current supply.

Valid CEPs for this substance (49)

HolderCountryCertificateIssued
Altergon ItaliaIT
CEP 2014-263 - Rev 02
Sodium hyaluronate, Intrinsic viscosity 0.2-3.2 m3/kg, by fermentation, for parenteral administration including intra-articular administration and intra-ocular use
Oct 2026
Altergon ItaliaIT
CEP 2026-262 - Rev 00
Sodium hyaluronate, Intrinsic viscosity 0.8 m3/kg, 1.4 m3/kg, 1.8 m3/kg, 2.4 m3/kg; by fermentation; for parenteral administration other than intra-articular administration
Sept 2026
AMHWA BIOPHARM CO LTDCN
CEP 2021-235 - Rev 02
Sodium hyaluronate, Intrinsic viscosity: 2.93 m3/kg, from fermentation, for parenteral administration, including intra-articular administration, and for intra-ocular use
Aug 2026
AMHWA BIOPHARM CO LTDCN
CEP 2021-234 - Rev 02
Sodium hyaluronate, Intrinsic viscosity 2.12 m3/kg, from fermentation, for parenteral administration, including intra-articular administration, and for intra-ocular use
Aug 2026
CONTIPRO ASCZ
CEP 2003-194 - Rev 04
Sodium hyaluronate, Intrinsic viscosity: not less than 0.65 m3/kg; by fermentation, for parenteral administration including intra-articular use and intra-ocular use
Jul 2026
KIKKOMAN BIOCHEMIFA COJP
CEP 2016-247 - Rev 01
Sodium hyaluronate, Grade 80; intrinsic viscosity 1.70 m3/kg; from fermentation, for parenteral administration, including intra-ocular use
Jun 2026
KEWPIE CORPJP
CEP 2025-641 - Rev 00
Sodium hyaluronate, HYALURONASAN HA-SHL 150: Intrinsic viscosity 2.00 m3/kg, by fermentation, for parenteral administration including intra-articular administration and for intra-ocular use
May 2026
SHANDONG FOCUSFREDA BIOTECH CO LTDCN
CEP 2025-464 - Rev 00
Sodium hyaluronate, Intrinsic viscosity 3.0 m3/kg, by fermentation, for parenteral administration including intra-articular administration and for intra-ocular use
May 2026
KIKKOMAN BIOCHEMIFA COJP
CEP 2020-420 - Rev 01
Sodium hyaluronate, GS-100, intrinsic viscosity: 1.50 m3/kg; from fermentation; for parenteral administration, including intra-ocular use
Dec 2025
AMHWA BIOPHARM CO LTDCN
CEP 2018-285 - Rev 02
Sodium hyaluronate, Intrinsic viscosity 1.55 m3/kg, by fermentation, for parenteral administration including intra-articular administration and for intra-ocular use
Sept 2025
MARUHA NICHIRO CORPJP
CEP 2007-242 - Rev 02
Sodium hyaluronate, Intrinsic viscosity: 1.62m3/kg - 1.70m3/kg and 2.28m3/kg - 3.78m3/kg; from fermentation; for parenteral administration, including intra-articular administration and intra-ocular use
Aug 2025
KIKKOMAN BIOCHEMIFA COJP
CEP 2020-138 - Rev 01
Sodium hyaluronate, GS-200; intrinsic viscosity 2.77 m3/kg; from fermentation; for parenteral administration, including intra-ocular use
Jul 2025
KEWPIE CORPJP
CEP 2019-064 - Rev 01
Sodium hyaluronate, Intrinsic viscosity 2.93 m3/kg, by fermentation, for parenteral administration including intra-articular administration and for intra-ocular use
Jul 2025
KIKKOMAN BIOCHEMIFA COJP
CEP 2023-034 - Rev 02
Sodium hyaluronate, GS-120, intrinsic viscosity: 1.7 m3/kg; from fermentation; for parenteral administration, including intra-ocular use
Apr 2025
KEWPIE CORPJP
CEP 2018-037 - Rev 03
Sodium hyaluronate, Intrinsic viscosity 1.28 m3/kg; 1.63 m3/kg, by fermentation, for parenteral administration including intra-articular administration and for intra-ocular use
Mar 2025
SHANDONG FOCUSFREDA BIOTECH CO LTDCN
CEP 2021-388 - Rev 01
Sodium hyaluronate, Intrinsic viscosity 2.3 m3/kg, by fermentation, for parenteral administration other than intra-articular administration and intra-ocular use
Feb 2025
CONTIPRO ASCZ
CEP 2024-332 - Rev 00
Sodium hyaluronate, Intrinsic viscosity: 2.50 m3/kg; by fermentation; for non-parenteral use
Dec 2024
BLOOMAGE BIOTECHNOLOGY CORP., LTD. Jinan CNCN
CEP 2010-290 - Rev 04
Sodium hyaluronate, HA-EP 3.0 (intrinsic viscosity: 2.7-3.6 m3/kg); from fermentation; for parenteral administration including intra-articular administration and intra-ocular use
Jul 2024
HTLFR
CEP 2012-335 - Rev 03
Sodium hyaluronate, Alternative process; Intrinsic viscosity : less than 1.8 m3/kg, by fermentation, for parenteral and ophthalmic administration including intra-articular use and intra-ocular use
Jul 2024
HTLFR
CEP 2001-385 - Rev 09
Sodium hyaluronate, Intrinsic viscosity: 1.7 m3/kg, 1.9 m3/kg, 2.4 m3/kg, 2.8 m3/kg, or 3.5 m3/kg, by fermentation, for parenteral administration including intra-articular use and intra-ocular use
Jul 2024
HTLFR
CEP 2004-238 - Rev 06
Sodium hyaluronate, Intrinsic viscosity 0.2 to 2.4 m3/kg; by fermentation; for parenteral administration and for intra-ocular and intra-articular use
Jul 2024
KIKKOMAN BIOCHEMIFA COJP
CEP 2022-341 - Rev 00
Sodium hyaluronate, GS-300, intrinsic viscosity: 3.8 m3/kg; from fermentation; for parenteral administration, including intra-ocular use
Jul 2024
BLOOMAGE BIOTECHNOLOGY CORP., LTD. Jinan CNCN
CEP 2021-220 - Rev 02
Sodium hyaluronate, Intrinsic viscosity 1.8 m3/kg, by fermentation, for parenteral administration including intra-articular administration and for intra-ocular use
Jun 2024
BLOOMAGE BIOTECHNOLOGY CORP., LTD. Jinan CNCN
CEP 2017-195 - Rev 01
Sodium hyaluronate, Intrinsic viscosity 2.5 m3/kg, by fermentation, for parenteral administration including intra-articular administration and for intra-ocular use
May 2024
Fidia Farmaceutici S.p.A.IT
CEP 2017-220 - Rev 01
Sodium hyaluronate, Intrinsic viscosity: 0.5 m3/kg; 1.25 m3/kg; 2.0 m3/kg; 2.67 m3/kg; from fermentation; for cutaneous and parenteral administration, including intra-articular administration, and for intra-ocular use.
Apr 2024
BLOOMAGE BIOTECHNOLOGY CORP., LTD. Jinan CNCN
CEP 2015-200 - Rev 01
Sodium hyaluronate, HA-E2.0 (intrinsic viscosity 1.2-2.8 m3/kg), from fermentation, for parenteral administration other than intra-articular administration and intra-ocular use
Mar 2024
Altergon ItaliaIT
CEP 2014-263 - Rev 01
Sodium hyaluronate, Intrinsic viscosity 0.2-3.2 m3/kg, by fermentation, for parenteral administration including intra-articular administration and intra-ocular use
Mar 2024
BLOOMAGE BIOTECHNOLOGY CORP., LTD. Jinan CNCN
CEP 2018-107 - Rev 04
Sodium hyaluronate, Intrinsic viscosity 2.4 m3/kg, by fermentation, for parenteral administration including intra-articular administration and for intra-ocular use
Feb 2024
LIFECORE BIOMEDICAL LLCUS
CEP 2021-250 - Rev 00
Sodium hyaluronate, Intrinsic viscosity 3.4 m3/kg, by fermentation, sterile, for intra-ocular use
Oct 2023
BLOOMAGE BIOTECHNOLOGY CORP., LTD. Jinan CNCN
CEP 2010-289 - Rev 04
Sodium hyaluronate, HA-EP 1.8 (intrinsic viscosity: 1.6-2.2 m3/kg); from fermentation; for parenteral administration including intra-articular administration and intra-ocular use
Sept 2023
BLOOMAGE BIOTECHNOLOGY CORP., LTD. Jinan CNCN
R0-CEP 2021-446 - Rev 01
Sodium hyaluronate, Intrinsic viscosity 0.6 m3/kg and 0.8 m3/kg, by fermentation, for parenteral administration including intra-articular administration and for intra-ocular use
Jun 2023
BLOOMAGE BIOTECHNOLOGY CORP., LTD. Jinan CNCN
R0-CEP 2022-129 - Rev 01
Sodium hyaluronate, Intrinsic viscosity 3.8 m3/kg, by fermentation, for parenteral administration including intra-articular administration and for intra-ocular use
May 2023
BLOOMAGE BIOTECHNOLOGY CORP., LTD. Jinan CNCN
R1-CEP 2016-172 - Rev 00
Sodium hyaluronate, Intrinsic viscosity 1.4 m3/kg and 1.0 m3/kg, by fermentation, for parenteral administration including intra-articular administration and for intra-ocular use
May 2023
BLOOMAGE BIOTECHNOLOGY CORP., LTD. Jinan CNCN
R0-CEP 2021-258 - Rev 02
Sodium hyaluronate, Intrinsic viscosity 1.25 m3/kg, by fermentation, for parenteral administration including intra-articular administration and for intra-ocular use
Mar 2023
Fidia Farmaceutici S.p.A.IT
R0-CEP 2023-001 - Rev 00
Sodium hyaluronate, Intrinsic viscosity: 0.5 m3/kg; 0.83 m3/kg and 1.25 m3/kg; from fermentation; for cutaneous and parenteral administration, including intra-articular administration, and for intra-ocular use.
Feb 2023
SHANDONG TOPSCIENCE BIOTECH CO LTDCN
R0-CEP 2022-269 - Rev 00
Sodium hyaluronate, intrinsic viscosity 1.66 m3/kg, 2.27 m3/kg, 3.30 m3/kg; from fermentation; for parenteral administration including intra-articular administration and intra-ocular use
Jan 2023
AMHWA BIOPHARM CO LTDCN
R0-CEP 2021-235 - Rev 01
Sodium hyaluronate, Intrinsic viscosity: 2.93 m3/kg, from fermentation, for parenteral administration, including intra-articular administration, and for intra-ocular use
Jun 2022
SHANDONG TOPSCIENCE BIOTECH CO LTDCN
R1-CEP 2013-348 - Rev 01
Sodium hyaluronate, SH 2.2; intrinsic viscosity 2.2 m3/kg, from fermentation; for parenteral administration including intra-articular administration and intra-ocular use
May 2022
SHANDONG TOPSCIENCE BIOTECH CO LTDCN
R1-CEP 2015-261 - Rev 01
Sodium hyaluronate, SH 1.3; intrinsic viscosity 1.3 m3/kg, from fermentation; for parenteral administration including intra-articular administration and intra-ocular use
May 2022
SHANDONG TOPSCIENCE BIOTECH CO LTDCN
R1-CEP 2013-349 - Rev 01
Sodium hyaluronate, SH 3.0; intrinsic viscosity 3.0 m3/kg, from fermentation; for parenteral administration including intra-articular administration and intra-ocular use
Mar 2022
Fidia Farmaceutici S.p.A.IT
R0-CEP 2021-428 - Rev 00
Sodium hyaluronate, Intrinsic viscosity: 1.6 m3/kg; 2.0 m3/kg and 2.5 m3/kg; from fermentation; for cutaneous and parenteral administration, including intra-articular administration, and for intra-ocular use.
Feb 2022
BLOOMAGE BIOTECHNOLOGY CORP., LTD. Jinan CNCN
R1-CEP 2015-201 - Rev 00
Sodium hyaluronate, HA-E3.0 (intrinsic viscosity 2.7-3.6 m3/kg), from fermentation, for parenteral administration other than intra-articular administration and intra-ocular use
Nov 2021
LIFECORE BIOMEDICAL LLCUS
R1-CEP 2004-285 - Rev 05
Sodium hyaluronate, Intrinsic viscosity ranges: 0.3-0.9 m3/kg, 1.0-2.3 m3/kg and 1.8-3.1 m3/kg; by fermentation; for parenteral administration and for intra-ocular and intra-articular use after appropriate sterilisation
Mar 2021
CONTIPRO ASCZ
R1-CEP 2010-330 - Rev 01
Sodium hyaluronate, Type II (intrinsic viscosity: not higher than 0.70 m3/kg), from fermentation, for parenteral administration including intra-articular administration and intra-ocular use
Oct 2017
Fidia Farmaceutici S.p.A.IT
R1-CEP 2009-015 - Rev 01
Sodium hyaluronate, Intrinsic viscosity: 2.0-3.4 m3/kg, from fermentation; for parenteral administration, including intra-articular administration, and for intra-ocular use
Jun 2015
Bio-Technology General (Israel) Ltd. Kiryat Malachi ILIL
R1-CEP 2002-243 - Rev 00
Sodium hyaluronate, Intrinsic viscosity 2.7-3.6 m3/kg, by fermentation, for parenteral administration including intra-articular and intra-ocular use
Jul 2010
Fidia Farmaceutici S.p.A.IT
R1-CEP 2001-249 - Rev 02
Sodium hyaluronate, Intrinsic viscosity: 1.0-1.5 m3/kg, by fermentation, for intra-articular use
Oct 2009
Fidia Farmaceutici S.p.A.IT
R1-CEP 2001-250 - Rev 01
Sodium hyaluronate, Intrinsic viscosity: 0.3 - 0.6 m3/kg, by fermentation, for cutaneous use
Oct 2008
Fidia Farmaceutici S.p.A.IT
R1-CEP 2001-248 - Rev 01
Sodium hyaluronate, Intrinsic viscosity: 1.7-2.1 m3/kg, by fermentation, for intra-ocular use
Jul 2008

Certification Online Database, European Directorate for the Quality of Medicines & HealthCare. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Inactive filings (2)

  • KYOWA HAKKO KOGYO CO LTD · SODIUM HYALURONATEDMF 11366 · Feb 1995
  • QP CORP · SODIUM HYALURONATEDMF 10091 · Feb 1993

Inactive filings are closed or lapsed and cannot be referenced. They are shown as history only.

What these records establish

  • A Type IV DMF is a confidential file held by the FDA for an excipient, colourant or flavour. The FDA does not approve or disapprove it; it is reviewed when a drug application references it.
  • Active means the file is open and can be referenced with the holder's letter of authorisation. It says nothing about price, capacity or current availability.
  • The holder is the organisation that filed. It is usually, but not always, the manufacturer.
  • Many excipients are supplied without any DMF, so this list is not every supplier of Sodium Hyaluronate.

How to qualify an excipient supplier

For suppliers

Do you supply Sodium Hyaluronate?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.